Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder that occurs frequently in women of childbearing age and is associated with insulin resistance. Serum visfatin can affect insulin resistance by binding to insulin receptors and further affect the occurrence and development of PCOS. In this study, we investigated the current status of serum visfatin levels in patients with PCOS through a literature search and meta-analysis.
Methods: We searched online Pubmed, Embase, Web of Science, the Cochrane Library, CNKI (China National Knowledge Infrastructure), CBMdisc (China Biology Medicine disc) databases and registered websites such as the ICTRP (International Clinical Trial Registration Platform) and clinicaltrials.gov (https://clinicaltrials.gov/) for case-control studies on PCOS and visfatin levels, assessed the quality of the included articles with the Newcastle-Ottawa Scale (NOS scale), and combined the comparison of serum visfatin levels between patients with PCOS and healthy individuals from high-quality studies.
Results: 20 research papers were included in the quantitative analysis of this study. The combined analysis showed that obese patients with PCOS had statistically significantly higher visfatin levels than healthy people [MD (mean difference) = 12.94, 95% CI (confidence interval) (6.52-19.37), Z = 3.95, p < 0.0001]. Visfatin levels were higher in non-obese patients with PCOS than in healthy people and are statistically significant [MD = 14.98, 95% CI (5.80-24.16), Z = 3.20, p = 0.001]. Heterogeneity in the combined analysis was not related to study location, the publication year of the literature, source of serum samples, but was influenced by the quality of the literature. After excluding the most influential papers, the combined analysis was conducted again, and the conclusion was consistent with that before the exclusion. The results of Egger's test showed no significant publication bias.
Conclusions: High serum visfatin levels are a natural feature of PCOS and are not associated with obesity; Serum visfatin levels may be a potential marker for the diagnosis of PCOS, but their relationship with PCOS and insulin resistance remains worthy of in-depth investigation.
背景:多囊卵巢综合征(PCOS)是一种常见于育龄妇女的内分泌紊乱，与胰岛素抵抗有关。血清visfatin可通过与胰岛素受体结合影响胰岛素抵抗，进而影响PCOS的发生发展。在这项研究中，我们通过文献检索和荟萃分析调查了PCOS患者血清visfatin水平的现状。方法:我们检索了Pubmed、Embase、Web of Science、Cochrane Library、CNKI(中国国家知识基础设施)、CBMdisc(中国生物医学磁盘)数据库和注册了ICTRP(国际临床试验注册平台)和clinicaltrials.gov (https://clinicaltrials.gov/)等网站，检索了PCOS和visfatin水平的病例对照研究，用纽卡斯尔-渥太华量表(NOS)评估了纳入文章的质量。并结合高质量研究中多囊卵巢综合征患者和健康人血清内脂素水平的比较。结果:20篇研究论文被纳入本研究的定量分析。综合分析显示，肥胖多囊卵巢综合征患者的visfatin水平显著高于健康人群[MD (mean difference) = 12.94, 95% CI (confidence interval) (6.52 ~ 19.37)， Z = 3.95, p < 0.0001]。非肥胖多囊卵巢综合征患者Visfatin水平高于健康人群，差异有统计学意义[MD = 14.98, 95% CI (5.80-24.16)， Z = 3.20, p = 0.001]。联合分析的异质性与研究地点、文献发表年份、血清样本来源无关，但受文献质量的影响。排除最具影响力的论文后，再次进行联合分析，结论与排除前一致。Egger的检验结果显示没有显著的发表偏倚。结论:高血脂水平是多囊卵巢综合征的自然特征，与肥胖无关;血清visfatin水平可能是PCOS诊断的潜在指标，但其与PCOS和胰岛素抵抗的关系仍值得深入研究。
{"title":"Risk Correlation Analysis between Polycystic Ovary Syndrome (PCOS) and Serum Visfatin Levels in Middle-Aged Women: Systematic Review and Meta-Analysis.","authors":"Jie Chen, Lingmin Hu, Yingchun Ling, Yuhua Xu, Xiao Yu, Luping Ma, Mengna Shou","doi":"10.24976/Discov.Med.202335175.17","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335175.17","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovary syndrome (PCOS) is an endocrine disorder that occurs frequently in women of childbearing age and is associated with insulin resistance. Serum visfatin can affect insulin resistance by binding to insulin receptors and further affect the occurrence and development of PCOS. In this study, we investigated the current status of serum visfatin levels in patients with PCOS through a literature search and meta-analysis.</p><p><strong>Methods: </strong>We searched online Pubmed, Embase, Web of Science, the Cochrane Library, CNKI (China National Knowledge Infrastructure), CBMdisc (China Biology Medicine disc) databases and registered websites such as the ICTRP (International Clinical Trial Registration Platform) and clinicaltrials.gov (https://clinicaltrials.gov/) for case-control studies on PCOS and visfatin levels, assessed the quality of the included articles with the Newcastle-Ottawa Scale (NOS scale), and combined the comparison of serum visfatin levels between patients with PCOS and healthy individuals from high-quality studies.</p><p><strong>Results: </strong>20 research papers were included in the quantitative analysis of this study. The combined analysis showed that obese patients with PCOS had statistically significantly higher visfatin levels than healthy people [MD (mean difference) = 12.94, 95% CI (confidence interval) (6.52-19.37), Z = 3.95, <i>p</i> < 0.0001]. Visfatin levels were higher in non-obese patients with PCOS than in healthy people and are statistically significant [MD = 14.98, 95% CI (5.80-24.16), Z = 3.20, <i>p</i> = 0.001]. Heterogeneity in the combined analysis was not related to study location, the publication year of the literature, source of serum samples, but was influenced by the quality of the literature. After excluding the most influential papers, the combined analysis was conducted again, and the conclusion was consistent with that before the exclusion. The results of Egger's test showed no significant publication bias.</p><p><strong>Conclusions: </strong>High serum visfatin levels are a natural feature of PCOS and are not associated with obesity; Serum visfatin levels may be a potential marker for the diagnosis of PCOS, but their relationship with PCOS and insulin resistance remains worthy of in-depth investigation.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 175","pages":"168-177"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9449803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.24976/Discov.Med.202335175.18
Hua-Zun Yuan, Li Zhao, Yun-Lan Tao, Jian-Yong Ding, Gang Chen
Objective: Thymoma is a slow-growing epithelial tumor of thymus gland. Its size is associated with its prognosis. The aim of this study was to analyze the prognostic correlation of tumor volume and complete resection of thymoma at different Masaoka-Koga stages.
Methods: A retrospective study was carried out, using the data of 502 patients who underwent complete resection of thymectomy at Zhongshan Hospital, Fudan University, in Shanghai, China, from February 2009 to February 2016. The characteristics of the patients were collected. Using Masaoka-Koga staging system, patients were divided into four different subcohorts: Stage I, stage II, stage III and stage IVa/IVb. The relationship between tumor volume and postoperative recurrence was analyzed for each subcohort, using receiver operating curves, cutoff values were obtained. and patients were grouped according to the cutoff values. Survival analysis was performed with the help of Kaplan-Meier method, and the difference between the two survival curves was compared using log-rank test. Whether tumor volume could be used as an independent risk factor for thymoma prognosis was analyzed, using a univariate Cox proportional hazards model.
Results: The area under the curve was 0.718, 0.740, 0.798, and 0.804 for the stage I, II, III, and IVa/IVb subcohorts, respectively, and the cutoff values of tumor volume for predicting recurrence were 47.90 cm3, 53.70 cm3, 76.35 cm3, and 89.05 cm3, respectively. Patients with tumor volumes greater than the cutoff values had significantly shorter recurrence-free survival than those with tumor volumes less than the cutoff values (p < 0.001). The results of the univariate Cox proportional hazards model indicated that tumor volume was an independent risk factor for thymoma prognosis and for postoperative prognosis of thymoma in Masaoka-Koga stage I (p < 0.001).
Conclusions: Tumor volume is significantly correlated with the postoperative prognosis of thymoma in Masaoka-Koga stage I and can serve as an independent risk factor for predicting postoperative tumor recurrence.
{"title":"Prognostic Correlation between Tumor Volume and Complete Resection of Thymoma at Different Masaoka-Koga Stages.","authors":"Hua-Zun Yuan, Li Zhao, Yun-Lan Tao, Jian-Yong Ding, Gang Chen","doi":"10.24976/Discov.Med.202335175.18","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335175.18","url":null,"abstract":"<p><strong>Objective: </strong>Thymoma is a slow-growing epithelial tumor of thymus gland. Its size is associated with its prognosis. The aim of this study was to analyze the prognostic correlation of tumor volume and complete resection of thymoma at different Masaoka-Koga stages.</p><p><strong>Methods: </strong>A retrospective study was carried out, using the data of 502 patients who underwent complete resection of thymectomy at Zhongshan Hospital, Fudan University, in Shanghai, China, from February 2009 to February 2016. The characteristics of the patients were collected. Using Masaoka-Koga staging system, patients were divided into four different subcohorts: Stage I, stage II, stage III and stage IVa/IVb. The relationship between tumor volume and postoperative recurrence was analyzed for each subcohort, using receiver operating curves, cutoff values were obtained. and patients were grouped according to the cutoff values. Survival analysis was performed with the help of Kaplan-Meier method, and the difference between the two survival curves was compared using log-rank test. Whether tumor volume could be used as an independent risk factor for thymoma prognosis was analyzed, using a univariate Cox proportional hazards model.</p><p><strong>Results: </strong>The area under the curve was 0.718, 0.740, 0.798, and 0.804 for the stage I, II, III, and IVa/IVb subcohorts, respectively, and the cutoff values of tumor volume for predicting recurrence were 47.90 cm<sup>3</sup>, 53.70 cm<sup>3</sup>, 76.35 cm<sup>3</sup>, and 89.05 cm<sup>3</sup>, respectively. Patients with tumor volumes greater than the cutoff values had significantly shorter recurrence-free survival than those with tumor volumes less than the cutoff values (<i>p</i> < 0.001). The results of the univariate Cox proportional hazards model indicated that tumor volume was an independent risk factor for thymoma prognosis and for postoperative prognosis of thymoma in Masaoka-Koga stage I (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Tumor volume is significantly correlated with the postoperative prognosis of thymoma in Masaoka-Koga stage I and can serve as an independent risk factor for predicting postoperative tumor recurrence.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 175","pages":"178-184"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Systemic sclerosis (SSc) have been classified in two clinical subsets (diffuse and limited) based on the extend of skin thickening. In this study, we classified a novel subset of SSc defined rapidly progressive systemic sclerosis (RPSSc), which based on the rate of skin thickening progression and the progressive of interstitial lung disease (ILD). We aimed to evaluate RPSSc clinical characteristics and predictive factors in a Chinese single center.
Method: Overall, 75 patients diagnosed with SSc, classified into RPSSc (n = 14) and non-rapidly progressive SSc (non-RPSSc, n = 61) were retrospectively included in the study. Clinical characteristics, disease severity and autoantibodies were collected. Logistic regression, least absolute shrinkage, and selection operator (LASSO) regression analysis was used to identify RPSSc predictors. Receiver operating characteristic (ROC) analysis and Delong test was conducted to evaluate and compare different indexes.
Results: RPSSc rate was 18.7%. ILD (64.3%), cardiac involvement (42.9%) were the most common organ system involvement of RPSSc, while Raynaud's phenomenon incidence significantly decreased. Disease duration (12 vs 72, months), sex (42.9% vs 11.5%, male %), SSc subset (85.7% vs 27.9%, diffuse cutaneous SSc (dsSSc) %), modified Rodnan total skin score (mRSS) (20.5 vs 6), Raynaud's phenomenon (64.3% vs 98.4%), cardiac involvement (42.9% vs 18%), higher incidence with malignancy (28.6% vs 1.6%) and positive anti-RNA polymerase III antibodies (ARA) (64.3% vs 1.6%) were statistically significant differences among the RPSSc groups and non-RPSSc groups (p < 0.05). Univariate analysis showed that positive ARA, male, dsSSc and malignancy were RPSSc risk factors, while long-disease duration, Raynaud's phenomenon was RPSSc protective factors. ARA was the strongest factor associated to RPSSc (OR 108, 95% CI 11.287-1033.327, p < 0.001). LASSO logistic regression model identified six factors: Disease duration, dsSSc, malignancy, cardiac involvement, positivity of ARA were RPSSc risk factors, Raynaud's phenomenon was RPSSc protective factors.
Conclusions: RPSSc is an SSc clinical category which should be accounted for early detection of organ involvement and close follow-up of malignancy. ARA might be used as a predictor for RPSSc and organ involvement.
目的:根据皮肤增厚的程度，系统性硬化症(SSc)被分为两个临床亚群(弥漫性和局限性)。在这项研究中，我们根据皮肤增厚进展的速度和间质性肺疾病(ILD)的进展，对SSc的一个新子集进行了分类，定义为快速进行性系统性硬化症(RPSSc)。我们的目的是评估中国单中心RPSSc的临床特征和预测因素。方法:回顾性研究75例确诊为SSc的患者，分为RPSSc (n = 14)和非快速进展型SSc (n = 61)。收集临床特征、疾病严重程度及自身抗体。采用Logistic回归、最小绝对收缩和选择算子(LASSO)回归分析来确定RPSSc的预测因子。采用受试者工作特征(ROC)分析和Delong检验对各指标进行评价和比较。结果:RPSSc率为18.7%。ILD(64.3%)、心脏受累(42.9%)是RPSSc最常见的脏器系统受累，雷诺现象发生率显著降低。病程(12个月vs 72个月)、性别(42.9% vs 11.5%，男性%)、SSc亚群(85.7% vs 27.9%，弥漫性皮肤SSc (dsSSc) %)、改良罗德曼皮肤总评分(mRSS) (20.5 vs 6)、Raynaud现象(64.3% vs 98.4%)、心脏受损伤(42.9% vs 18%)、较高的恶性肿瘤发生率(28.6% vs 1.6%)和抗rna聚合酶III抗体(ARA)阳性(64.3% vs 1.6%)在RPSSc组和非RPSSc组之间差异均有统计学意义(p < 0.05)。单因素分析显示，ARA阳性、男性、dsSSc和恶性肿瘤是RPSSc的危险因素，病程长、雷诺现象是RPSSc的保护因素。ARA是与RPSSc相关性最强的因素(OR 108, 95% CI 11.287-1033.327, p < 0.001)。LASSO logistic回归模型确定病程、dsSSc、恶性、心脏受累、ARA阳性为RPSSc的危险因素，雷诺现象为RPSSc的保护因素。结论:RPSSc是SSc的临床分类，应及早发现脏器受累，并密切随访恶性肿瘤。ARA可作为RPSSc和器官受累的预测因子。
{"title":"Clinical Features and Risk Factors of Rapidly Progressive Systemic Sclerosis in a Single Center in China: Anti-RNA Polymerase III Antibodies as a Predictor.","authors":"Qiuxia Yu, Jin Zhang, Liyi Fan, Tianhang Yu, Bingbing Liu, Jian Ding","doi":"10.24976/Discov.Med.202335175.20","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335175.20","url":null,"abstract":"<p><strong>Objectives: </strong>Systemic sclerosis (SSc) have been classified in two clinical subsets (diffuse and limited) based on the extend of skin thickening. In this study, we classified a novel subset of SSc defined rapidly progressive systemic sclerosis (RPSSc), which based on the rate of skin thickening progression and the progressive of interstitial lung disease (ILD). We aimed to evaluate RPSSc clinical characteristics and predictive factors in a Chinese single center.</p><p><strong>Method: </strong>Overall, 75 patients diagnosed with SSc, classified into RPSSc (n = 14) and non-rapidly progressive SSc (non-RPSSc, n = 61) were retrospectively included in the study. Clinical characteristics, disease severity and autoantibodies were collected. Logistic regression, least absolute shrinkage, and selection operator (LASSO) regression analysis was used to identify RPSSc predictors. Receiver operating characteristic (ROC) analysis and Delong test was conducted to evaluate and compare different indexes.</p><p><strong>Results: </strong>RPSSc rate was 18.7%. ILD (64.3%), cardiac involvement (42.9%) were the most common organ system involvement of RPSSc, while Raynaud's phenomenon incidence significantly decreased. Disease duration (12 vs 72, months), sex (42.9% vs 11.5%, male %), SSc subset (85.7% vs 27.9%, diffuse cutaneous SSc (dsSSc) %), modified Rodnan total skin score (mRSS) (20.5 vs 6), Raynaud's phenomenon (64.3% vs 98.4%), cardiac involvement (42.9% vs 18%), higher incidence with malignancy (28.6% vs 1.6%) and positive anti-RNA polymerase III antibodies (ARA) (64.3% vs 1.6%) were statistically significant differences among the RPSSc groups and non-RPSSc groups (<i>p</i> < 0.05). Univariate analysis showed that positive ARA, male, dsSSc and malignancy were RPSSc risk factors, while long-disease duration, Raynaud's phenomenon was RPSSc protective factors. ARA was the strongest factor associated to RPSSc (OR 108, 95% CI 11.287-1033.327, <i>p</i> < 0.001). LASSO logistic regression model identified six factors: Disease duration, dsSSc, malignancy, cardiac involvement, positivity of ARA were RPSSc risk factors, Raynaud's phenomenon was RPSSc protective factors.</p><p><strong>Conclusions: </strong>RPSSc is an SSc clinical category which should be accounted for early detection of organ involvement and close follow-up of malignancy. ARA might be used as a predictor for RPSSc and organ involvement.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 175","pages":"193-200"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Hepatitis B virus (HBV) genome structure is an incomplete closed double stranded circular DNA and it uses covalently closed circular DNA (cccDNA) as template for replication. To study the antiviral effect on different HBV replication forms, a stable cell line expressing HBV using Huh7 cells with shuttle plasmid to imitate the real HBV replication form was stablished. Unlike the HepG2.2.15 cells, the replication of HBV-expressing Huh7 cells present significant decrease after 9 days of interferon-α (IFN-α) treatment. This study aimed to verify whether hepatitis B virus X (HBx) epigenetic regulation by HBV promoter is affected by the DNA form and discuss the differences between the episomal form and the integrated form.
Material and methods: Huh7 cells were used with two different plasmids containing HBV genome to imitate HBV-expressing cells with the episomal form and the integrated form. Luciferase reporting system was used to determine the activation of the promoter after treatment with IFN-α with different concentrations and promoter regulation factor HBx. HBx-expressing plasmid was transfected to evaluate its effect on HBV replication in the episomal form. HBV DNA and pregenomic RNA (pgRNA) in HBx knockdown cell line was determined and HBx-expressing plasmid was transfected to evaluate its effect on HBx in the episomal form.
Results: The two cell lines were established successfully and used for further experiments after selection. IFN-α showed significant inhibition effect on HBV pregenome promoter in the episomal form DNA while was not observed in the integrated form. After HBx-expressing plasmid was transfected, HBV pregenome promoter activity was higher in the episomal form rather than the integrated form. HBx showed a concentration-dependant activation on HBV replication in the episomal form. HBx knockdown reduced HBV production and HBV concentration significantly increased after transfection by HBx-expressing plasmid.
Conclusions: HBx regulation effect on HBV pregenome promoter is influenced by the HBV genome form. The epigenetic regulation effect on HBV pregenome promoter is more active in the episomal form rather than the integrated form.
{"title":"HBx Regulation on HBV Pregenome Promoter in the Episomal Form Versus the Integrated Form.","authors":"Hui Ding, Shuang Hu, Huihui Zhu, Ziyang Liu, Yuan Li, Jianping Liu, Xiaofang Li, Shuangyin Han, Suofeng Sun","doi":"10.24976/Discov.Med.202335175.13","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335175.13","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis B virus (HBV) genome structure is an incomplete closed double stranded circular DNA and it uses covalently closed circular DNA (cccDNA) as template for replication. To study the antiviral effect on different HBV replication forms, a stable cell line expressing HBV using Huh7 cells with shuttle plasmid to imitate the real HBV replication form was stablished. Unlike the HepG2.2.15 cells, the replication of HBV-expressing Huh7 cells present significant decrease after 9 days of interferon-α (IFN-α) treatment. This study aimed to verify whether hepatitis B virus X (HBx) epigenetic regulation by HBV promoter is affected by the DNA form and discuss the differences between the episomal form and the integrated form.</p><p><strong>Material and methods: </strong>Huh7 cells were used with two different plasmids containing HBV genome to imitate HBV-expressing cells with the episomal form and the integrated form. Luciferase reporting system was used to determine the activation of the promoter after treatment with IFN-α with different concentrations and promoter regulation factor HBx. HBx-expressing plasmid was transfected to evaluate its effect on HBV replication in the episomal form. HBV DNA and pregenomic RNA (pgRNA) in HBx knockdown cell line was determined and HBx-expressing plasmid was transfected to evaluate its effect on HBx in the episomal form.</p><p><strong>Results: </strong>The two cell lines were established successfully and used for further experiments after selection. IFN-α showed significant inhibition effect on HBV pregenome promoter in the episomal form DNA while was not observed in the integrated form. After HBx-expressing plasmid was transfected, HBV pregenome promoter activity was higher in the episomal form rather than the integrated form. HBx showed a concentration-dependant activation on HBV replication in the episomal form. HBx knockdown reduced HBV production and HBV concentration significantly increased after transfection by HBx-expressing plasmid.</p><p><strong>Conclusions: </strong>HBx regulation effect on HBV pregenome promoter is influenced by the HBV genome form. The epigenetic regulation effect on HBV pregenome promoter is more active in the episomal form rather than the integrated form.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 175","pages":"124-130"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9449802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The long intergenic non-coding RNA 01614 (LINC01614) is aberrantly expressed in various malignancies, suggesting its role in oncogenesis. However, it has not been well studied in breast cancer.
Methods: The cancer genome atlas databases (TCGA) and public database of breast cancer gene-expression miner (bc-GenExMiner) were utilized to analyze the prognostic role of LINC01614 in breast cancer. Kaplan-Meier, and Cox regression analyses were conducted for survival analysis. Nomograms were built to predict survival. We used deconvolution-based methods, such as TIMER (Tumor Immune Estimation Resource) and CIBERSORT (cell-type identification by estimating relative subsets of RNA transcripts), to explore the relationship between LINC01614 and immune cell characteristics.
Results: The very abnormal expression of LINC01614 was found in 14 types of malignancy, including breast cancer. The LINC01614 was significantly overexpressed in human epidermal growth factor receptor 2 (HER2)+, estrogen receptor (ER)+, progesterone receptor (PR)+, and non-triple negative breast cancer (non-TNBC). According to survival analysis, the higher expression of LINC01614 was related with poor survival. The co-expressed genes analysis exhibited that LINC01614 was closely associated with the collagen-associated process and phosphoinositide 3-kinases-protein kinase B (PI3K-Akt) signaling pathway. Moreover, this study has explored the association among LINC01614 expression, tumor-infiltrating immune cells, and the efficacy of chemotherapeutics.
Conclusions: Our data reveal the expression pattern of LINC01614 in breast carcinoma with different molecular subtypes. The results also indicated that the LINC01614 could be a novel diagnostic and prognostic marker for breast carcinoma.
{"title":"Long Noncoding RNA LINC01614 is a Diagnostic and Prognostic Marker for Breast Cancer.","authors":"Wei Li, Yun Cheng, Junchi Cheng, Jincao Yao, Mei Song, Meiying Yan, Yajun Qi","doi":"10.24976/Discov.Med.202335174.3","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335174.3","url":null,"abstract":"<p><strong>Background: </strong>The long intergenic non-coding RNA 01614 (LINC01614) is aberrantly expressed in various malignancies, suggesting its role in oncogenesis. However, it has not been well studied in breast cancer.</p><p><strong>Methods: </strong>The cancer genome atlas databases (TCGA) and public database of breast cancer gene-expression miner (bc-GenExMiner) were utilized to analyze the prognostic role of LINC01614 in breast cancer. Kaplan-Meier, and Cox regression analyses were conducted for survival analysis. Nomograms were built to predict survival. We used deconvolution-based methods, such as TIMER (Tumor Immune Estimation Resource) and CIBERSORT (cell-type identification by estimating relative subsets of RNA transcripts), to explore the relationship between LINC01614 and immune cell characteristics.</p><p><strong>Results: </strong>The very abnormal expression of LINC01614 was found in 14 types of malignancy, including breast cancer. The LINC01614 was significantly overexpressed in human epidermal growth factor receptor 2 (HER2)+, estrogen receptor (ER)+, progesterone receptor (PR)+, and non-triple negative breast cancer (non-TNBC). According to survival analysis, the higher expression of LINC01614 was related with poor survival. The co-expressed genes analysis exhibited that LINC01614 was closely associated with the collagen-associated process and phosphoinositide 3-kinases-protein kinase B (PI3K-Akt) signaling pathway. Moreover, this study has explored the association among LINC01614 expression, tumor-infiltrating immune cells, and the efficacy of chemotherapeutics.</p><p><strong>Conclusions: </strong>Our data reveal the expression pattern of LINC01614 in breast carcinoma with different molecular subtypes. The results also indicated that the LINC01614 could be a novel diagnostic and prognostic marker for breast carcinoma.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 174","pages":"19-27"},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9451470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.24976/Discov.Med.202335174.2
Yanzhu Wang, Xue Li, Kadiya Abudukeyimu, Wenzheng Du, Yuxian Ning, Xiaoli Qi, Ning Hua, Nan Wei, Gang Ding, Jing Li, Linlin Song, Ying Zhang, Xuehan Qian
Background: There are some uncertainties about the effect of low-power red laser treatment on myopia control for anisometropic myopia in children. To evaluate the effect and safety of low-power red laser treatment on refractive development for anisometropic myopia in children, a contralateral comparison study was conducted.
Methods: The more myopic eye of child with anisometropic myopia was treated with low-power red laser treatment (LRL group), the other eye received no treatment other than the wearing of single-focus spectacles (SFS) (SFS Group). The LRL treatment was given at home under parental guidance for 3 minutes each time, twice daily with a minimal interval of 4 hours, 7 days per week, using an equipment that produces red laser of 650 nm wavelength at an illuminance range of roughly 1200-1800 lux and an energy of 0.60 mw for a 4-mm pupil (class I classification).
Results: Among 51 included children, 44 (86.27%) completed the 3-months study, consisting of 15 girls (34.1%) and 29 boys (65.9%). After 3-months axial length (AL) and spherical equivalent refraction (SER) progression were -0.08 mm [95% CI (confidence interval), 0.11 to 0.06 mm] and +0.23 diopter (D) (95% CI, 0.13-0.33 D) for LRL group and +0.08 mm (95% CI, 0.05-0.11 mm) and -0.07 D (95% CI, -0.16-0.03 D) for SFS group. AL and SER progression between the groups varied by 0.17 mm (95% CI, 0.13-0.20 mm) and -0.30 D (95% CI, -0.42 to -0.18 D). There was no visible structural damage on optical coherence tomography (OCT) scans.
Conclusions: AL growth, myopia progression, and anisometropia of the binoculars can all be slowed down by LRL treatment. Compared to SER progression, axial elongation is more accurate and simpler to monitor. LRL treatment unrecorded functional and structural damage of binoculus.
背景:低功率红色激光治疗对儿童屈光参差性近视的控制效果尚存在一些不确定性。为了评价低功率红色激光治疗儿童屈光参差性近视的疗效和安全性，进行了对侧比较研究。方法:对屈光参差性近视患儿的较近视眼进行低功率红色激光治疗(LRL组)，另一只眼不进行任何治疗，仅配戴单焦眼镜(SFS组)。LRL治疗在父母的指导下在家中进行，每次3分钟，每天两次，最少间隔4小时，每周7天，使用的设备产生650 nm波长的红色激光，照度范围约为1200-1800勒克斯，能量为0.60 mw, 4毫米瞳孔(I类分类)。结果:51例患儿中，44例(86.27%)完成了为期3个月的研究，其中女孩15例(34.1%)，男孩29例(65.9%)。3个月后，LRL组的轴长(AL)和球面等效折射(SER)进展为-0.08 mm [95% CI(置信区间)，0.11至0.06 mm]和+0.23屈光度(D) (95% CI, 0.13-0.33 D)， SFS组为+0.08 mm (95% CI, 0.05-0.11 mm)和-0.07 D (95% CI， -0.16-0.03 D)。两组间AL和SER进展差异分别为0.17 mm (95% CI, 0.13-0.20 mm)和-0.30 D (95% CI， -0.42 - -0.18 D)，光学相干断层扫描(OCT)未见明显的结构损伤。结论:LRL治疗可减缓AL生长、近视进展和双眼屈光参差。与SER进展相比，轴向伸长率更准确，更容易监测。LRL治疗未记录的双眼功能和结构损伤。
{"title":"Low-Power Red Laser Treatment for Anisometropic Myopia Control in Children: A Contralateral Comparison Study.","authors":"Yanzhu Wang, Xue Li, Kadiya Abudukeyimu, Wenzheng Du, Yuxian Ning, Xiaoli Qi, Ning Hua, Nan Wei, Gang Ding, Jing Li, Linlin Song, Ying Zhang, Xuehan Qian","doi":"10.24976/Discov.Med.202335174.2","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335174.2","url":null,"abstract":"<p><strong>Background: </strong>There are some uncertainties about the effect of low-power red laser treatment on myopia control for anisometropic myopia in children. To evaluate the effect and safety of low-power red laser treatment on refractive development for anisometropic myopia in children, a contralateral comparison study was conducted.</p><p><strong>Methods: </strong>The more myopic eye of child with anisometropic myopia was treated with low-power red laser treatment (LRL group), the other eye received no treatment other than the wearing of single-focus spectacles (SFS) (SFS Group). The LRL treatment was given at home under parental guidance for 3 minutes each time, twice daily with a minimal interval of 4 hours, 7 days per week, using an equipment that produces red laser of 650 nm wavelength at an illuminance range of roughly 1200-1800 lux and an energy of 0.60 mw for a 4-mm pupil (class I classification).</p><p><strong>Results: </strong>Among 51 included children, 44 (86.27%) completed the 3-months study, consisting of 15 girls (34.1%) and 29 boys (65.9%). After 3-months axial length (AL) and spherical equivalent refraction (SER) progression were -0.08 mm [95% CI (confidence interval), 0.11 to 0.06 mm] and +0.23 diopter (D) (95% CI, 0.13-0.33 D) for LRL group and +0.08 mm (95% CI, 0.05-0.11 mm) and -0.07 D (95% CI, -0.16-0.03 D) for SFS group. AL and SER progression between the groups varied by 0.17 mm (95% CI, 0.13-0.20 mm) and -0.30 D (95% CI, -0.42 to -0.18 D). There was no visible structural damage on optical coherence tomography (OCT) scans.</p><p><strong>Conclusions: </strong>AL growth, myopia progression, and anisometropia of the binoculars can all be slowed down by LRL treatment. Compared to SER progression, axial elongation is more accurate and simpler to monitor. LRL treatment unrecorded functional and structural damage of binoculus.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 174","pages":"11-18"},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9451469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.24976/Discov.Med.202335174.5
Zengding Zhou, Huizhong Yang, Xiqiao Wang, Lei Yi
Background: Cardiovascular disease, one of the most common types of disease in clinical practice today, carries a very high risk of disability and death. This research aims to examine genome-wide changes in injured human dermal microvascular endothelial cells (HDMECs) using the Ribonucleic Acid sequencing (RNA-Seq) technique, and to search for key genes influencing N6-methyladenosine (m6A) methylation, thus gaining new insights into future clinical diagnosis and treatment of cardiovascular diseases (CVDs) and laying a foundation for follow-up research.
Methods: Impaired HDMECs (injury group), established by endotoxin intervention, were analyzed by RNA-Seq for differentially expressed genes (DEGs) relative to normal HDMECs (control group). Then, DEGs that might be associated with m6A methylation were selected for expression blocking to observe m6A methylation alterations. The migration, angiogenesis, and inflammatory response of damaged HDMECs were detected by cell scratch assay, western blotting, and Enzyme-linked Immunosorbent Assay (ELISA) experiments, respectively.
Results: In this study, 20 DEGs were screened out from the two groups by RNA-Seq, of which 17 were up-regulated and 3 were down-regulated. The C-C motif chemokine receptor 10 (CCR10) was selected for subsequent analysis. Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) identified elevated CCR10 expression and reduced m6A methylation levels in the injury group (p < 0.05). After blocking CCR10 expression in damaged HDMECs by BI6901 (a CCR10 specific blocker) m6A methylation, cell activity, vascular endothelial growth factor A (VEGFA) and CD31 protein expression, as well as relative length and branches of tube formation were found to be increased compared with the injury group, while the levels of inflammatory factors interleukin-1 (IL-1), interleukin-1 (IL-6) and tumor necrosis factor-α (TNF-α) were decreased (p < 0.05).
Conclusions: Blocking CCR10 expression can activate m6A methylation, promote cell activity, inhibit inflammatory reactions and alleviate HDMEC injury, which may become a breakthrough in future diagnosis and treatment of cardiovascular diseases.
{"title":"Blocking <i>CCR10</i> Expression Activates m6A Methylation and Alleviates Vascular Endothelial Cell Injury.","authors":"Zengding Zhou, Huizhong Yang, Xiqiao Wang, Lei Yi","doi":"10.24976/Discov.Med.202335174.5","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335174.5","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease, one of the most common types of disease in clinical practice today, carries a very high risk of disability and death. This research aims to examine genome-wide changes in injured human dermal microvascular endothelial cells (HDMECs) using the Ribonucleic Acid sequencing (RNA-Seq) technique, and to search for key genes influencing N6-methyladenosine (m6A) methylation, thus gaining new insights into future clinical diagnosis and treatment of cardiovascular diseases (CVDs) and laying a foundation for follow-up research.</p><p><strong>Methods: </strong>Impaired HDMECs (injury group), established by endotoxin intervention, were analyzed by RNA-Seq for differentially expressed genes (DEGs) relative to normal HDMECs (control group). Then, DEGs that might be associated with m6A methylation were selected for expression blocking to observe m6A methylation alterations. The migration, angiogenesis, and inflammatory response of damaged HDMECs were detected by cell scratch assay, western blotting, and Enzyme-linked Immunosorbent Assay (ELISA) experiments, respectively.</p><p><strong>Results: </strong>In this study, 20 DEGs were screened out from the two groups by RNA-Seq, of which 17 were up-regulated and 3 were down-regulated. The C-C motif chemokine receptor 10 (<i>CCR10</i>) was selected for subsequent analysis. Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) identified elevated <i>CCR10</i> expression and reduced m6A methylation levels in the injury group (<i>p</i> < 0.05). After blocking <i>CCR10</i> expression in damaged HDMECs by BI6901 (a <i>CCR10</i> specific blocker) m6A methylation, cell activity, vascular endothelial growth factor A (VEGFA) and CD31 protein expression, as well as relative length and branches of tube formation were found to be increased compared with the injury group, while the levels of inflammatory factors interleukin-1 (IL-1), interleukin-1 (IL-6) and tumor necrosis factor-α (TNF-α) were decreased (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Blocking <i>CCR10</i> expression can activate m6A methylation, promote cell activity, inhibit inflammatory reactions and alleviate HDMEC injury, which may become a breakthrough in future diagnosis and treatment of cardiovascular diseases.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 174","pages":"36-44"},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9451473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.24976/Discov.Med.202335174.1
Yan Ma, Xiaoguang Huo, Shanshan Kong, Wenzhe Xu, Wei Zhao, Min Zhu
Purpose: This study aimed to evaluate the diagnostic efficiency of the Chinese version of thyroid imaging reporting and data system (C-TIRADS), American College of Radiology (ACR)-TIRADS, and Korean (K)-TIRADS combined with real-time tissue elastography to diagnose thyroid nodules.
Methods: A total of 574 thyroid nodule ultrasonographic images were retrospectively analyzed and classified based on the three TIRADS methods. The MedCale statistical software was used to construct the receiver operating characteristic (ROC) curve based on the pathological results of surgery. The diagnostic efficiency before and after assessing elastographies from the three TIRADS was compared between C-TIRADS, ACR-TIRADS, and K-TIRADS groups and within before and after TIRADS combined with elastic imaging. Furthermore, the unnecessary biopsy rates were also compared. Comparing area under ROC curve (AUC) with MEDCALC software (20.0.15, MedCalc Software Ltd., Ostend, Belgium), Delong test was used. The sensitivity and specificity were compared by STATA software (15.1, StataCorp LP, College Station, TX, USA) and Chi-square test. The rate of unnecessary biopsy was compared by SPSS software (23.0, IBM, Armonk, NY, USA) and Chi-square test.
Results: C-TIRADS, ACR-TIRADS, K-TIRADS cut-off values, and real-time tissue elastography (RTE) were 4b, 5, 5, and 3, respectively, and the areas under the ROC curve were 0.932, 0.914, 0.904, and 0.883, respectively. C-TIRADS had the highest AUC (p < 0.05) and sensitivity (p < 0.001), while ACR-TIRADS had the highest specificity (p < 0.001). After conducting a combined elastography with the three TIRADS, AUC showed increases of different degrees. Comparing TIRADS with TIRADS+RTE, the difference of C-TIRADS had statistical significance (p < 0.001), but the difference of ACR-TIRADS and K-TIRADS had no statistical significance (p > 0.05). The unnecessary biopsy rate showed decreases of different degrees. Differences between C-TIRADS and K-TIRADS were significant (p < 0.05), but in the case of ACR-TIRADS were not significant (p > 0.05).
Conclusions: C-TIRADS, ACR-TIRADS, K-TIRA and RTE showed high diagnostic efficiency, with C-TIRADS having the highest. Real-time tissue elastography can improve TIRADS diagnostic efficiency and reduce its unnecessary biopsy rate. In this case C-TIRADS showed again the highest efficiency.
{"title":"A Review about C-TIRADS, ACR-TIRADS, and K-TIRADS Combined with Real-Time Tissue Elastography to Diagnose Thyroid Nodules.","authors":"Yan Ma, Xiaoguang Huo, Shanshan Kong, Wenzhe Xu, Wei Zhao, Min Zhu","doi":"10.24976/Discov.Med.202335174.1","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335174.1","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the diagnostic efficiency of the Chinese version of thyroid imaging reporting and data system (C-TIRADS), American College of Radiology (ACR)-TIRADS, and Korean (K)-TIRADS combined with real-time tissue elastography to diagnose thyroid nodules.</p><p><strong>Methods: </strong>A total of 574 thyroid nodule ultrasonographic images were retrospectively analyzed and classified based on the three TIRADS methods. The MedCale statistical software was used to construct the receiver operating characteristic (ROC) curve based on the pathological results of surgery. The diagnostic efficiency before and after assessing elastographies from the three TIRADS was compared between C-TIRADS, ACR-TIRADS, and K-TIRADS groups and within before and after TIRADS combined with elastic imaging. Furthermore, the unnecessary biopsy rates were also compared. Comparing area under ROC curve (AUC) with MEDCALC software (20.0.15, MedCalc Software Ltd., Ostend, Belgium), Delong test was used. The sensitivity and specificity were compared by STATA software (15.1, StataCorp LP, College Station, TX, USA) and Chi-square test. The rate of unnecessary biopsy was compared by SPSS software (23.0, IBM, Armonk, NY, USA) and Chi-square test.</p><p><strong>Results: </strong>C-TIRADS, ACR-TIRADS, K-TIRADS cut-off values, and real-time tissue elastography (RTE) were 4b, 5, 5, and 3, respectively, and the areas under the ROC curve were 0.932, 0.914, 0.904, and 0.883, respectively. C-TIRADS had the highest AUC (<i>p</i> < 0.05) and sensitivity (<i>p</i> < 0.001), while ACR-TIRADS had the highest specificity (<i>p</i> < 0.001). After conducting a combined elastography with the three TIRADS, AUC showed increases of different degrees. Comparing TIRADS with TIRADS+RTE, the difference of C-TIRADS had statistical significance (<i>p</i> < 0.001), but the difference of ACR-TIRADS and K-TIRADS had no statistical significance (<i>p</i> > 0.05). The unnecessary biopsy rate showed decreases of different degrees. Differences between C-TIRADS and K-TIRADS were significant (<i>p</i> < 0.05), but in the case of ACR-TIRADS were not significant (<i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>C-TIRADS, ACR-TIRADS, K-TIRA and RTE showed high diagnostic efficiency, with C-TIRADS having the highest. Real-time tissue elastography can improve TIRADS diagnostic efficiency and reduce its unnecessary biopsy rate. In this case C-TIRADS showed again the highest efficiency.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 174","pages":"1-10"},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9451468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.24976/Discov.Med.202335174.8
Zongpan Wang, Rongxing Wu, Dan Qiu, Shaofang Zhou
Background: Whether to perform surgery on breast cancer with initial bone metastasis is heatedly debated. The aim of this study was to assess the efficacy of surgery to prolong survival time towards breast cancer patients with bone-only metastasis, and create a prognostic nomogram to predict long-term survival.
Methods: Patients diagnosed with bone-only metastatic breast cancer from 2010 to 2015 were included in this study. National Cancer Database (NCDB) was used to obtain patients' data.
Results: A total of 7751 patients were included for final analysis, among which 3114 (40.2%) patients had received specialized breast surgery and 4637 (59.8%) had not. Patients who had undergone surgery showed a superior overall survival (OS) compared to patients without surgery (multivariate: HR (hazard ratios) = 0.58; 95% CI (confidence interval) [0.54-0.62]; p < 0.001). Moreover, survival benefit from surgery was also true in almost all subgroups. Prognostic nomogram to individually predict patients' long-term survival rate exhibited an acceptable predictive capability, with a C-index around 0.7 both in training and validation cohorts. Clinicopathological factors included in the nomogram could discriminate patients into subgroup with different prognoses.
Conclusions: Our data suggests that surgery may enhance OS in patients with initial bone-only metastatic breast cancer. Additionally, the created nomogram showed an acceptable could predict patients' long term survival.
{"title":"Clinical Value of Surgery and Establishment a Predictive Model for Breast Cancer Patients with Bone-Only Metastasis.","authors":"Zongpan Wang, Rongxing Wu, Dan Qiu, Shaofang Zhou","doi":"10.24976/Discov.Med.202335174.8","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335174.8","url":null,"abstract":"<p><strong>Background: </strong>Whether to perform surgery on breast cancer with initial bone metastasis is heatedly debated. The aim of this study was to assess the efficacy of surgery to prolong survival time towards breast cancer patients with bone-only metastasis, and create a prognostic nomogram to predict long-term survival.</p><p><strong>Methods: </strong>Patients diagnosed with bone-only metastatic breast cancer from 2010 to 2015 were included in this study. National Cancer Database (NCDB) was used to obtain patients' data.</p><p><strong>Results: </strong>A total of 7751 patients were included for final analysis, among which 3114 (40.2%) patients had received specialized breast surgery and 4637 (59.8%) had not. Patients who had undergone surgery showed a superior overall survival (OS) compared to patients without surgery (multivariate: HR (hazard ratios) = 0.58; 95% CI (confidence interval) [0.54-0.62]; <i>p</i> < 0.001). Moreover, survival benefit from surgery was also true in almost all subgroups. Prognostic nomogram to individually predict patients' long-term survival rate exhibited an acceptable predictive capability, with a C-index around 0.7 both in training and validation cohorts. Clinicopathological factors included in the nomogram could discriminate patients into subgroup with different prognoses.</p><p><strong>Conclusions: </strong>Our data suggests that surgery may enhance OS in patients with initial bone-only metastatic breast cancer. Additionally, the created nomogram showed an acceptable could predict patients' long term survival.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 174","pages":"73-81"},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND The aberrant expression of adipocyte enhancer binding protein 1 (AEBP1) has been observed in many cancers and it seems to be involved in the tumorigenesis, progression, and metastasis in numerous tumor types. However, the contribution of AEBP1 in breast cancer (BCa) remains inexplicable. METHODS Information related to the diagnostic significance and expression of AEBP1 in BCa was obtained from the public dataset Kaplan-Meier Plotter (http://kmplot.com/analysis/) and the dataset UALCAN (https://ualcan.path.uab.edu/index.html). The MTT (methyl thiazolyl tetrazolium) assay, colony formation assay, Transwell® assay, and FACS (fluorescence-activated cell sorting) assay were used to detect the proliferation, invasive and apoptotic ability of cells before and after treatment. In addition, we constructed an AEBP1 overexpression vector and silenced AEBP1, combined with Real-Time Quantitative Reverse Transcription PCR (qRT-PCR), western blot, immunohistochemistry and TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling) assay to investigate the prognostic significance, biological functions and potential mechanisms of AEBP1 in BCa. RESULTS Higher expression of AEBP1 mRNA (message RNA) was observed in BCa patients with later-stage, who obtained poorer overall survival. Meanwhile, compared with adjacent noncancerous tissues, AEBP1 protein expression was dramatically upregulated in the BCa ones. Furthermore, overexpressed AEBP1 enhanced cell proliferation, migration, invasion, and blocked cell apoptosis in BCa cells. Moreover, the research certificated that AEBP1 upregulated the expression of MMP (matrix metalloproteinase)-2, 9, vimentin, N-cadherin (neural-cadherin), phosphorylation of ERK (extracellular signal-regulated kinase), Smad2/3 (Abbreviated from Sma for nematode and Mad for Drosophila) and AKT (V-akt murine thymoma viral oncogene homolog), while down-regulated the expression of E-cadherin (epithelial cadherin) and PTEN (phosphatase and tensin homolog deleted on chromosome 10). To inhibit cell apoptosis, enforced expression of AEBP1 effectively blocked the cleavage of caspase 9 and p53 (protein 53) and promoted the expression of anti-apoptotic protein Bcl-2 (B-cell lymphoma-2). Finally, AEBP1 accelerated subcutaneously transplanted tumor growth in nude mice by increasing the expression of the cell proliferation biomarker ki67, the phosphorylation of AKT, and blocked apoptosis in vivo. CONCLUSIONS In summary, these data suggested the important role of AEBP1 in the BCa progression, which could be used as a potential biomarker for prognostic hallmark and a novel therapeutic strategy.
{"title":"AEBP1 Contributes to Breast Cancer Progression by Facilitating Cell Proliferation, Migration, Invasion, and Blocking Apoptosis.","authors":"Jin Li, Yanyun Ruan, Chenhui Zheng, Yue Pan, Bangyi Lin, Qi Chen, Zhibao Zheng","doi":"10.24976/Discov.Med.202335174.6","DOIUrl":"https://doi.org/10.24976/Discov.Med.202335174.6","url":null,"abstract":"BACKGROUND The aberrant expression of adipocyte enhancer binding protein 1 (AEBP1) has been observed in many cancers and it seems to be involved in the tumorigenesis, progression, and metastasis in numerous tumor types. However, the contribution of AEBP1 in breast cancer (BCa) remains inexplicable. METHODS Information related to the diagnostic significance and expression of AEBP1 in BCa was obtained from the public dataset Kaplan-Meier Plotter (http://kmplot.com/analysis/) and the dataset UALCAN (https://ualcan.path.uab.edu/index.html). The MTT (methyl thiazolyl tetrazolium) assay, colony formation assay, Transwell® assay, and FACS (fluorescence-activated cell sorting) assay were used to detect the proliferation, invasive and apoptotic ability of cells before and after treatment. In addition, we constructed an AEBP1 overexpression vector and silenced AEBP1, combined with Real-Time Quantitative Reverse Transcription PCR (qRT-PCR), western blot, immunohistochemistry and TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling) assay to investigate the prognostic significance, biological functions and potential mechanisms of AEBP1 in BCa. RESULTS Higher expression of AEBP1 mRNA (message RNA) was observed in BCa patients with later-stage, who obtained poorer overall survival. Meanwhile, compared with adjacent noncancerous tissues, AEBP1 protein expression was dramatically upregulated in the BCa ones. Furthermore, overexpressed AEBP1 enhanced cell proliferation, migration, invasion, and blocked cell apoptosis in BCa cells. Moreover, the research certificated that AEBP1 upregulated the expression of MMP (matrix metalloproteinase)-2, 9, vimentin, N-cadherin (neural-cadherin), phosphorylation of ERK (extracellular signal-regulated kinase), Smad2/3 (Abbreviated from Sma for nematode and Mad for Drosophila) and AKT (V-akt murine thymoma viral oncogene homolog), while down-regulated the expression of E-cadherin (epithelial cadherin) and PTEN (phosphatase and tensin homolog deleted on chromosome 10). To inhibit cell apoptosis, enforced expression of AEBP1 effectively blocked the cleavage of caspase 9 and p53 (protein 53) and promoted the expression of anti-apoptotic protein Bcl-2 (B-cell lymphoma-2). Finally, AEBP1 accelerated subcutaneously transplanted tumor growth in nude mice by increasing the expression of the cell proliferation biomarker ki67, the phosphorylation of AKT, and blocked apoptosis in vivo. CONCLUSIONS In summary, these data suggested the important role of AEBP1 in the BCa progression, which could be used as a potential biomarker for prognostic hallmark and a novel therapeutic strategy.","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 174","pages":"45-56"},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号